Long-Term Offspring Outcomes Following Parental Exposure to BCR::ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Retrospective Cohort Study with Follow-Up to 24.6 Years
Sándor Pál, Margit Solymár, Hussain Alizadeh · 2026
Read Long-Term Offspring Outcomes Following Parental Exposure to BCR::ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Retrospective Cohort Study with Follow-Up to 24.6 Years by Sándor Pál, Margit Solymár, Hussain Alizadeh (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13565506.txt.
Description
Sándor Pál, Margit Solymár, and Hussain Alizadeh published a 2026 study of the long-term health of children whose parents took tyrosine kinase inhibitors for chronic myeloid leukemia. These drugs transformed the outlook for this blood cancer, but evidence about offspring exposed before conception or during pregnancy has been limited. Nervous parents need follow-up measured in decades, not months.
The single-centre study followed patients with chronic-phase disease who had a pregnancy, or whose partner did, in association with drug exposure. Offspring health was tracked through adolescence and early adulthood, with follow-up reaching 24.6 years. The authors describe pregnancy outcomes and later health in this cohort. Long-term data of this kind directly inform counseling for patients who want children during treatment.
Catalog record
| CREATOR | Sándor Pál, Margit Solymár, Hussain Alizadeh |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |